Summary by Moomoo AI
Conchino Biologics announced on 29 April 2024 that it has signed a product transfer and technical licensing agreement with Shanghai Pharmaceutical Co., Ltd., which involves the transfer of the reconstituted Ebola virus vaccine (AD5-EBOV) and its global commercialization interests to the pharmaceutical Conchino. The total cost of the transaction was RMB14,417,100 and did not constitute a major asset restructuring. The transaction is a related transaction and has been approved by the Board of Directors and the Board of Directors and the Board of Supervisors is not subject to consideration by the General Meeting. Consino Bio said that this transaction is beneficial to the fair use of resources, will not have a significant adverse effect on the company's operations and will not affect the interests of shareholders, especially those of small and medium-sized shareholders.